
REVIEW


HUMAN GENOME EPIDEMIOLOGY (HuGE) REVIEW

1344 Association Between the Ubiquitin Carboxyl-Terminal Esterase L1 Gene (UCHL1) S18Y Variant and Parkinson’s Disease: A HuGE Review and Meta-Analysis. Margaret Ragland, Carolyn Hutter, Cyrus Zabetian, and Karen Edwards

ORIGINAL CONTRIBUTIONS

1358 Maternal Contributions to Preterm Delivery. Heather A. Boyd, Gry Poulsen, Jan Wohlfahrt, Jeffrey C. Murray, Bjarke Feenstra, and Mads Melbye

1365 Maternal Effects for Preterm Birth: A Genetic Epidemiologic Study of 630,000 Families. Anna C. Svensson, Sven Sandin, Sven Cnattingius, Marie Redy, Yudi Pawitan, Christina M. Huettman, and Paul Lichtenstein

1373 The Genetics of Preterm Birth: Using What We Know to Design Better Association Studies. Clarice R. Weinberg and Min Shi

1382 Invited Commentary: Maternal Effects in Preterm Birth — Effects of Maternal Genotype, Mitochondrial DNA, Imprinting, or Environment? Julian Little

1386 Svensson et al. Respond to “Maternal Genes and Environment in Preterm Birth.” Anna C. Svensson, Sven Sandin, Sven Cnattingius, Marie Redy, Yudi Pawitan, Christina M. Huettman, and Paul Lichtenstein

See the Evidence for Yourself

The only transparent IV site dressing integrated with a CHG gel pad proven to reduce skin flora better than BioPatch.

You know reducing skin flora at the catheter insertion site helps to reduce or prevent CRBSIs. The CDC recommends transparent dressings and the use of CHG to reduce skin flora at the IV site.

In studies, 3M® Tegaderm® CHG was proven to be:

- More effective than BioPatch® at preventing re-growth of skin flora on healthy volunteers at 7 days
- More effective than BioPatch® at detecting re-growth of skin flora on healthy volunteers at 7 days
- More effective than BioPatch® in overall performance, ease of applying correctly, and ability to see the IV site—as rated by 12 out of 12 clinicians

Tegaderm® CHG is the only transparent IV site dressing integrated with a CHG gel pad proven to reduce skin flora, a leading cause of CRBSIs.

Visit www.3M.com/tegadermchg to see the evidence for yourself.

Tegaderm™ CHG
Chlorhexidine Gluconate IV Securement Dressing

3M Tegaderm CHG Dressing has not been studied in a randomized, controlled trial as to its effectiveness in preventing CRBSIs. 1


© 2009 3M. 3M and Tegaderm are trademarks of 3M. BioPatch is a registered trademark of ETHICON, INC.

Contents Continued from Front Cover

1388 Timing and Trajectories of Fetal Growth Related to Cognitive Development in Childhood. Ondine S. von Ehrenstein, Rafael T. Mikolajczyk, and Jun Zhang

1396 Estimation of the Contribution of Non-Assisted Reproductive Technology Ovulation Stimulation Fertility Treatments to US Singleton and Multiple Births. Laura A. Schieve, Owen Devine, Coleen A. Boyle, Joann R. Petrini, and Lee Warner

1408 Use of Fertility Drugs and Risk of Uterine Cancer: Results From a Large Danish Population-based Cohort Study. Allan Jensen, Heidi Sharif, and Susanne K. Kjaer


1422 Mammographic Screening and Risk Factors for Breast Cancer. Nancy R. Cook, Bernard A. Rosner, Susan E. Hankinson, and Graham A. Colditz


PRACTICE OF EPIDEMIOLOGY


BOOK REVIEWS


1451 International Ethical Guidelines for Epidemiological Studies. Susan Rose

ERRATUM

1454 Re: “Good Semen Quality and Life Expectancy: A Cohort Study of 43,277 Men.”

Instructions to Authors can be found on the following website: http://aje.oxfordjournals.org/